Article

Targeted repair of heart injury by stem cells fused with platelet nanovesicles

  • Nature Biomedical Engineering 21726 (2018)
  • doi:10.1038/s41551-017-0182-x
  • Download Citation
Received:
Accepted:
Published online:

Abstract

Stem cell transplantation, as used clinically, suffers from low retention and engraftment of the transplanted cells. Inspired by the ability of platelets to recruit stem cells to sites of injury on blood vessels, we hypothesized that platelets might enhance the vascular delivery of cardiac stem cells (CSCs) to sites of myocardial infarction injury. Here, we show that CSCs with platelet nanovesicles fused onto their surface membranes express platelet surface markers that are associated with platelet adhesion to injury sites. We also find that the modified CSCs selectively bind collagen-coated surfaces and endothelium-denuded rat aortas, and that in rat and porcine models of acute myocardial infarction the modified CSCs increase retention in the heart and reduce infarct size. Platelet-nanovesicle-fused CSCs thus possess the natural targeting and repairing ability of their parental cell types. This stem cell manipulation approach is fast, straightforward and safe, does not require genetic alteration of the cells, and should be generalizable to multiple cell types.

  • Subscribe to Nature Biomedical Engineering for full access:

    $99

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Mozaffarian, D. et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131, 29–322 (2015).

  2. 2.

    Madonna, R. et al. Cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur. Heart J. 37, 1789–1798 (2016).

  3. 3.

    Sepantafar, M. et al. Stem cells and injectable hydrogels: synergistic therapeutics in myocardial repair. Biotechnol. Adv. 34, 362–379 (2016).

  4. 4.

    Weissman, I. L. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 287, 1442–1446 (2000).

  5. 5.

    Cheng, K. et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun. 5, 4880 (2014).

  6. 6.

    Tongers, J. et al. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur. Heart J. 32, 1197–1206 (2011).

  7. 7.

    van der Spoel, T. I. et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc. Res. 91, 649–658 (2011).

  8. 8.

    Lippi, G. et al. Arterial thrombus formation in cardiovascular disease. Nat. Rev. Cardiol. 8, 502–512 (2011).

  9. 9.

    Stellos, K. et al. Circulating platelet-progenitor cell coaggregate formation is increased in patients with acute coronary syndromes and augments recruitment of CD34+ cells in the ischaemic microcirculation. Eur. Heart J. 34, 2548–2556 (2013).

  10. 10.

    Li, T. S. et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59, 942–953 (2012).

  11. 11.

    Smith, R. R. et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115, 896–908 (2007).

  12. 12.

    Cheng, K. et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ. Res. 106, 1570–1581 (2010).

  13. 13.

    Lee, S. T. et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J. Am. Coll. Cardiol. 57, 455–465 (2011).

  14. 14.

    Cheng, K. et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail. 2, 49–61 (2014).

  15. 15.

    Malliaras, K. et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (cardiosphere-derived autologous stem cells to reverse ventricular dysfunction). J. Am. Coll. Cardiol. 63, 110–22 (2014).

  16. 16.

    Makkar, R. R. et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379, 895–904 (2012).

  17. 17.

    Cheng, K. et al. Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant. 21, 1121–1135 (2012).

  18. 18.

    Kanazawa, H. et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ. Heart Fail. 8, 322–332 (2015).

  19. 19.

    Nasiri, S. Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfus. 11, 337–342 (2013).

  20. 20.

    Hu, C. M. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015).

  21. 21.

    Cheng, K. et al. Brief report: mechanism of extravasation of infused stem cells. Stem Cells 30, 2835–2842 (2012).

  22. 22.

    Allen, T. A. et al. Angiopellosis as an alternative mechanism of cell extravasation. Stem Cells 35, 170–180 (2017).

  23. 23.

    Gawaz, M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc. Res. 61, 498–511 (2004).

  24. 24.

    Xu, Y. et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 290, H692–699 (2006).

  25. 25.

    Anselmo, A. C. et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 8, 11243–11253 (2014).

  26. 26.

    Vandergriff, A. C. et al. Magnetic targeting of cardiosphere-derived stem cells with ferumoxytol nanoparticles for treating rats with myocardial infarction. Biomaterials 35, 8528–8539 (2014).

  27. 27.

    Li, T. S. et al. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells 28, 2088–2098 (2010).

  28. 28.

    Li, C. et al. Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer. Biomaterials 54, 177–187 (2015).

  29. 29.

    Kawada, M. Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo. Int. J. Cancer 105, 520–526 (2003).

  30. 30.

    Lentz, B. R. Polymer-induced membrane fusion: potential mechanism and relation to cell fusion events. Chem. Phys. Lipids 73, 91–106 (1994).

  31. 31.

    Huang, Y. et al. Fusions of tumor-derived endothelial cells with densritic cells induces antitumor immunity. Sci. Rep. 7, 46544 (2017).

  32. 32.

    Brown, A. C. et al. Molecular interference of fibrin’s divalent polymerization mechanism enables modulation of multiscale material properties. Biomaterials 49, 27–36 (2015).

  33. 33.

    Brown, A. C. et al. Ultrasoft microgels displaying emergent platelet-like behaviours. Nat. Mater. 13, 1108–1114 (2014).

  34. 34.

    Tang, J. et al. Heart repair using nanogel-encapsulated human cardiac stem cells in mice and pigs with myocardial infarction. ACS Nano 11, 9738–9749 (2017).

  35. 35.

    Tang, J. et al. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat. Commun. 8, 13724 (2017).

Download references

Acknowledgements

This work was supported by US National Institute of Health (HL123920 and HL137093), NC State University Chancellor’s Faculty Excellence Program, NC State Chancellor’s Innovation Fund, University of North Carolina General Assembly Research Opportunities Initiative grant and the National Natural Science Foundation of China (81370216, 81570274).

Author information

Author notes

  1. Junnan Tang, Teng Su, Ke Huang and Phuong-Uyen Dinh contributed equally to this work.

Affiliations

  1. Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, USA

    • Junnan Tang
    • , Teng Su
    • , Ke Huang
    • , Phuong-Uyen Dinh
    • , Adam Vandergriff
    • , Michael T. Hensley
    • , Jhon Cores
    • , Tyler Allen
    • , Deliang Shen
    •  & Ke Cheng
  2. Joint Department of Biomedical Engineering and Comparative Medicine Institute, University of North Carolina at Chapel Hill & North Carolina State University, Raleigh, NC, USA

    • Junnan Tang
    • , Teng Su
    • , Adam Vandergriff
    • , Michael T. Hensley
    • , Jhon Cores
    • , Erin Sproul
    • , Emily Mihalko
    • , Ashley Brown
    • , Deliang Shen
    • , Zhen Gu
    •  & Ke Cheng
  3. Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

    • Junnan Tang
    • , Deliang Shen
    •  & Jinying Zhang
  4. The Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu, China

    • Zegen Wang
    •  & Ke Cheng
  5. Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

    • Taosheng Li
  6. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • Leonard J. Lobo
  7. Department of Clinical Sciences, North Carolina State University, Raleigh, NC, USA

    • Laura Ruterbories
    •  & Alex Lynch
  8. Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • Thomas G. Caranasos
  9. Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • George A. Stouffer
  10. Pharmacoengineering and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • Ke Cheng

Authors

  1. Search for Junnan Tang in:

  2. Search for Teng Su in:

  3. Search for Ke Huang in:

  4. Search for Phuong-Uyen Dinh in:

  5. Search for Zegen Wang in:

  6. Search for Adam Vandergriff in:

  7. Search for Michael T. Hensley in:

  8. Search for Jhon Cores in:

  9. Search for Tyler Allen in:

  10. Search for Taosheng Li in:

  11. Search for Erin Sproul in:

  12. Search for Emily Mihalko in:

  13. Search for Leonard J. Lobo in:

  14. Search for Laura Ruterbories in:

  15. Search for Alex Lynch in:

  16. Search for Ashley Brown in:

  17. Search for Thomas G. Caranasos in:

  18. Search for Deliang Shen in:

  19. Search for George A. Stouffer in:

  20. Search for Zhen Gu in:

  21. Search for Jinying Zhang in:

  22. Search for Ke Cheng in:

Contributions

J.T., T.S., K.H., P.-U.D. and K.C. designed the research, performed biochemical, cellular and animal experiments, analysed the data and drafted the paper. P.-U.D., Z.W., A.V., M.T.H., T.A., J.C., T.L., E.S., E.M., L.L., L.R., A.L., A.B., T.G.C., D.S., Z.G. and G.A.S. performed cellular and in vitro experiments, and/or provided comments to improve the paper. K.C. and J.Z. provided financial support. K.C. directed the research.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Ke Cheng.

Supplementary information

Videos

  1. Supplementary Video 1

    Angiogram showing blood flow before ischaemia.

  2. Supplementary Video 2

    Angiogram showing the location of balloon inflation and blood flow during ischaemia.

  3. Supplementary Video 3

    Angiogram showing blood flow after ischaemia.